{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:24:19Z","timestamp":1788279859078,"version":"build-2803163510"},"reference-count":20,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.5551\/jat.41798","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T22:10:05Z","timestamp":1517609405000},"page":"690-697","source":"Crossref","is-referenced-by-count":9,"title":["Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel"],"prefix":"10.5551","volume":"25","author":[{"given":"Hiroshi","family":"Komoda","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shiraki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Circulation Regulation in Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Nishikido","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Christofori P, Lanzoni A, Quartaroli M, Pastorino AM, Zancanaro C, Cominacini L, Gaviraghi G, Turon J: The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens, 2000; 18: 1429-1436","DOI":"10.1097\/00004872-200018100-00010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Keyselovic J, Martinka P, Batova Z, Gazova A, Godfraind T: Calcium channel blocker inhibits Western-type dietevoked atherosclerosis development in ApoE-deficient mice. J Pharmacol Exp Ther, 2005; 315: 320-328","DOI":"10.1124\/jpet.105.089847"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Pal\u00f9 C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P; European Lacidipine Study on Atherosclerosis investigators: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation, 2002; 106: 2422-2427","DOI":"10.1161\/01.CIR.0000039288.86470.DD"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ishii N, Matsumura T, Kinoshita H, Fukuda K, Motoshima H, Senokuchi T, Nakao S, Tsutsumi A, Kim-Mitsuyama S, Kawada T, Takeya M, Miyamura N, Nishikawa T, Araki E: Nifedipine induces peroxisome proliferator-activated receptor-\u03b3 activation in macrophages and suppresses the progression of atherclerosis in apolipoprotein E-deficient mice. Arterioscler Thomb Vasc Biol, 2010; 30: 1598-1605","DOI":"10.1161\/ATVBAHA.109.202309"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Henry PD, Bentley KI: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest, 1981; 68: 1366-1369","DOI":"10.1172\/JCI110384"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K: Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis, 2008; 19: 172-179","DOI":"10.1016\/j.atherosclerosis.2007.03.036"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kojima T, Miyauchi K, Yokoyama T, Yokoyama K, Kurata T, Suwa S, Kawamura M, Tamura H, Okazaki S, Inoue K, Fujiwara Y, Sumiyoshi M, Tanimoto K, Nakazato Y, Yamagami S, Hiro T, Komiyama N, Daida H: Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J, 2011; 75: 1071-1079","DOI":"10.1253\/circj.CJ-11-0141"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Libby P: Inflammation in atherosclerosis. Nature, 2002; 420: 868-874","DOI":"10.1038\/nature01323"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Moore KJ, Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell, 2011; 145: 341-355","DOI":"10.1016\/j.cell.2011.04.005"},{"key":"10","unstructured":"10) Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, Tada K: Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res, 1982; 42: 1530-1536"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kohro T, Tanaka T, Murakami T, Wada Y, Aburatani H, Hamakubo T, Kodama T: A comparison of differences in the gene expression profiles of phorbol 12-myristate 13-acetate differentiated THP-1 cells and human monocyte derived macrophage. J Atheroscler Thromb, 2004; 11: 88-97","DOI":"10.5551\/jat.11.88"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nakayama K, Nitto T, Inoue T, Node K: Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sci, 2008; 83: 339-345","DOI":"10.1016\/j.lfs.2008.06.026"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Noda K, Hosoya M, Nakajima S, Ohashi J, Fukumoto Y, Shimokawa H: Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice. Tohoku J Exp Med, 2012; 228: 305-315","DOI":"10.1620\/tjem.228.305"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M: Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens, 2005; 23: 1383-1389","DOI":"10.1097\/01.hjh.0000173521.91104.5f"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Matsui T, Yamagishi S, Nakamura K, Inoue H: Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells. J Int Med Res, 2006; 34: 671-675","DOI":"10.1177\/147323000603400613"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T: Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol, 2006; 546: 11-18","DOI":"10.1016\/j.ejphar.2006.07.030"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol, 2004; 43: 724-730","DOI":"10.1097\/00005344-200405000-00016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Takahashi K, Shimokado K, Yoshida M: SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition. Eur J Pharmacol, 2006; 552: 162-169","DOI":"10.1016\/j.ejphar.2006.09.028"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Shima E, Katsube M, Kato T, Kitagawa M, Hato F, Hino M, Takahashi T, Fujita H, Kitagawa S: Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens, 2008; 21: 78-84","DOI":"10.1038\/ajh.2007.13"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Qin Z: The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature. Atherosclerosis, 2012, 221: 2-11","DOI":"10.1016\/j.atherosclerosis.2011.09.003"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/8\/25_41798\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T04:52:11Z","timestamp":1533358331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/8\/25_41798\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.41798","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}